Susquehanna International Group’s Agile Therapeutics AGRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-71
Closed -$30K 14387
2022
Q1
$30K Sell
71
-2
-3% -$1.28K ﹤0.01% 12511
2021
Q4
$72K Buy
73
+66
+943% +$93.1K ﹤0.01% 12360
2021
Q3
$13K Sell
7
-1
-13% -$2.26K ﹤0.01% 12589
2021
Q2
$20K Sell
8
-65
-89% -$214K ﹤0.01% 12418
2021
Q1
$302K Buy
73
+53
+265% +$286K ﹤0.01% 10594
2020
Q4
$117K Sell
20
-95
-83% -$559K ﹤0.01% 10416
2020
Q3
$702K Sell
115
-34
-23% -$195K ﹤0.01% 6957
2020
Q2
$831K Sell
149
-75
-33% -$390K ﹤0.01% 6308
2020
Q1
$831K Buy
224
+98
+78% +$562K ﹤0.01% 5805
2019
Q4
$632K Buy
+126
New +$440K ﹤0.01% 6481
2019
Q3
Sell
-43
Closed -$126K 11039
2019
Q2
$126K Sell
43
-56
-57% -$156K ﹤0.01% 9497
2019
Q1
$300K Buy
99
+29
+41% +$61.5K ﹤0.01% 7215
2018
Q4
$81K Buy
+70
New +$107K ﹤0.01% 8313
2018
Q2
Sell
-6
Closed -$32K 10663
2018
Q1
$32K Sell
6
-19
-76% -$126K ﹤0.01% 9062
2017
Q4
$135K Buy
25
+19
+317% +$177K ﹤0.01% 8561
2017
Q3
$57K Buy
+6
New +$46.1K ﹤0.01% 8514

Other funds holding AGRX

Susquehanna International Group's AGRX Position: Q1 2023 in Review

Susquehanna International Group sold out of Agile Therapeutics (AGRX) in Q1 2023, closing a stake of 289 shares — an estimated $3.28K sold.

Susquehanna International Group first reported a position in AGRX in Q4 2016 and held it in 18 quarters. The position peaked at $1.23M in Q1 2020. 22 funds tracked by Wall St. Rank hold AGRX as of Q1 2023.

  • Susquehanna International Group reported no remaining Agile Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Susquehanna International Group sold 289 Agile Therapeutics shares in Q1 2023, an estimated $3.28K.
  • Susquehanna International Group first reported a position in Agile Therapeutics in Q4 2016 and held it in 18 quarters.
  • Susquehanna International Group's Agile Therapeutics position peaked at $1.23M in Q1 2020.
  • 22 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.